Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total ...

About ImPact Biotech ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin vascular targeted photodynamic (VTP) therapy ...

ABOUT CARVYKTI® (CILTACABTAGENE AUTOLEUCEL; CILTA-CEL) ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of ...

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 Mechelen, Belgium; May 14, 2025, 22:01 CET; ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Details of th EAST PRINCETON, N.J. (AP) — PDS Biotechnology Corporation (PDSB ... Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical ...